Simranjit Singh is the CEO of Guardant Health, a precision oncology company that launched the first FDA-approved blood test for genomic testing across all solid cancers about 2 years ago. And just recently, Guardant Health AMEA was involved in a partnership with Adicon Holdings Limited, a leading independent clinical laboratory company based in China, to boost global research and diagnostic oncology efforts. Simranjit Singh joins Michelle Martin on Money and Me as he gives a breakdown of Guardant’s portfolio and efforts to effectively revolutionise the continuum of cancer care and improve clinical outcomes for cancer patients.

Money and Me : Self-Employed? Tips to boost your CPF
25:02

Market View: When Does an AI Story Become a Meme Stock? From Smartbird to SpaceX
12:36

Market View: Can ST Engineering challenge DBS, how Space X is putting IPO money to work, why Bury won't bet against Space X, Salesforce, Yum Brands, Elite UK REIT, Nike
14:55